Lead Product(s): EG-009A
Therapeutic Area: Infections and Infectious Diseases Product Name: EG-009A
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Evergreen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 18, 2021
The purpose of the study is to evaluate the efficacy of Evergreen’s EG-009A drug candidate for the treatment of moderate to severe COVID-19 cases.